Preliminary results of botulinum toxin A switch after first detrusor injection failure as a treatment of neurogenic detrusor overactivity
Authors:
- 18 December 2014
- journal article
- research article
- Published by Wiley in Neurourology and Urodynamics
- Vol. 35 (2) , 267-270
Abstract
Aims To assess the results of onabotulinum toxin detrusor injections when abobotulinum toxin detrusor injection failed. Methods Twenty‐six patients, 15 women and 11 men, mean age 40.8 ± 12.7 years old, in whom a first injection of 750 U abobotulinum toxin in 20 sites failed in treating neurogenic detrusor overactivity, received onabotulinum toxin 300 U detrusor injections in 30 sites. Neurologic conditions were spinal cord injury in 14 cases, multiple sclerosis in nine, myelomeningocele in two and myelitis in one. Mean time between the two injections was 5.6 ± 1.4 months. Before and 6 weeks after each injection, patients carried out a 3‐day bladder diary and had urodynamics. The success was defined as the combination of a clean intermittent self‐catheterization number under 8 per 24 hr, urgency, urinary incontinence and detrusor overactivity relief. Results Out of 26 patients, the second injection was successful in 15 (57.7%). While the first injection of 750 U abobotulinum toxin had no impact at all, after 300 U onabotulinum toxin injection, the number of clean intermittent self‐catheterization decreased significantly (11.3 ± 2.1 vs. 6.4 ± 1.9, P = 0.01), 17/26 (65.4%) patients achieved continence, urgency was relieved in 18/26 (69.2%) and detrusor overactivity in 15/26 (57.7%). Conclusions In case of failure after a first detrusor injection of abobotulinum toxin, switching for onabotulinum toxin is efficient. Further investigations should be performed to assess whether the replacement of onabotulinum toxin by abobotulinum toxin provides the same results. Neurourol. Urodynam.Keywords
This publication has 24 references indexed in Scilit:
- Chapter 4: Guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO)Neurourology and Urodynamics, 2014
- Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB)Neurourology and Urodynamics, 2014
- Phase 3 Efficacy and Tolerability Study of OnabotulinumtoxinA for Urinary Incontinence From Neurogenic Detrusor OveractivityJournal of Urology, 2012
- Prospective Randomised Controlled Trial Comparing Trigone-Sparing versus Trigone-Including Intradetrusor Injection of AbobotulinumtoxinA for Refractory Idiopathic Detrusor OveractivityEuropean Urology, 2012
- Efficacy and Safety of OnabotulinumtoxinA in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity: A Randomised, Double-Blind, Placebo-Controlled TrialEuropean Urology, 2011
- Contemporary Management of Lower Urinary Tract Disease With Botulinum Toxin A: A Systematic Review of Botox (OnabotulinumtoxinA) and Dysport (AbobotulinumtoxinA)European Urology, 2011
- Efficacy of Botulinum Toxin A Injection for Neurogenic Detrusor Overactivity and Urinary Incontinence: A Randomized, Double-Blind TrialJournal of Urology, 2011
- Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivityScandinavian Journal of Urology and Nephrology, 2007
- What is the optimum dose of type A botulinum toxin for treating neurogenic bladder overactivity?BJU International, 2006
- BOTULINUM TOXIN TYPE A IS A SAFE AND EFFECTIVE TREATMENT FOR NEUROGENIC URINARY INCONTINENCE: RESULTS OF A SINGLE TREATMENT, RANDOMIZED, PLACEBO CONTROLLED 6-MONTH STUDYJournal of Urology, 2005